Developing Partnerships in the Biotech Sector

Biotechnology partnerships are often described in simple terms: one party has technology, another has capital, infrastructure, market access, or clinical reach. In cell therapy, that description is incomplete.

Cell therapy partnerships are more complex because the product is living, the manufacturing process is part of the product, and regulatory evidence must connect CMC, nonclinical rationale, clinical data, pharmacovigilance, and long-term follow-up. A partnership that ignores this complexity can create scientific ambiguity, regulatory delays, IP leakage, and financial exposure.

The business of biotechnology in the cell therapy scenario is therefore not only about deal-making. It is about building a development architecture, and biotech partnerships in cell therapy must be designed accordingly.

Why cell therapy partnerships are different

Traditional biotech collaborations may center around a molecule, a target, a patent, or a clinical asset. Cell therapy collaborations include all of that, but add several layers of complexity.

A cell therapy partnership may involve:

• starting material
• donor eligibility
• cell processing
• engineering technology
• analytical methods
• potency assays
• GMP/BPF manufacturing
• cryopreservation
• cold-chain logistics
• clinical trial sites
• pharmacovigilance
• long-term follow-up
• health economics
• reimbursement and access strategy
• data ownership
• regulatory submissions
• technology transfer
• intellectual property protection

Each of these layers can create value. Each can also create risk.

For NK and CAR-NK platforms, the challenge is even sharper. A partner may contribute a cell source, a CAR construct, a manufacturing process, a clinical network, a CDMO capability, funding, or regional access. But unless responsibilities and ownership are clearly defined, the collaboration can become difficult to govern.

Partnerships must begin with strategic fit

Not every capable partner is the right partner.

A good biotech partnership should begin with a strategic-fit analysis:

• Does the partner strengthen the target product profile?
• Does the partner reduce a real development bottleneck?
• Does the partner bring validated technical capabilities?
• Does the partner understand advanced therapy regulation?
• Does the partner have quality systems suitable for the work?
• Does the partner protect confidentiality and IP?
• Does the partner have realistic funding capacity?
• Does the partner accept phase-gated decision-making?
• Does the partner understand that clinical success is not guaranteed?
• Does the partner share the same view of territory, field, and commercialization?

In cell therapy, a partnership should not be formed only because there is enthusiasm around a platform. It should be formed because the collaboration makes the product more developable, more manufacturable, more regulator-ready, and more commercially realistic.

Governance is not bureaucracy; it is risk control

Advanced therapy partnerships require structured governance.

The governance model should define who decides, who recommends, who executes, and who has veto rights over reserved matters. This is especially important when a collaboration involves clinical development, manufacturing, regulatory submissions, public-sector access, or technology transfer.

A strong governance structure may include:

• joint steering committee
• scientific and clinical development committee
• CMC, manufacturing, and quality committee
• regulatory and market access committee
• finance, royalty, and audit committee
• defined escalation pathways
• phase-gate reviews
• go/no-go criteria
• reserved matters requiring formal approval

This structure is not administrative excess. It protects the program from uncontrolled spending, unauthorized regulatory communication, premature technology transfer, weak quality decisions, and misaligned commercial commitments.

IP protection must be designed before value is created

In biotechnology, IP is not only patents. It includes know-how, regulatory data, clinical data, analytical methods, process knowledge, manufacturing improvements, software, quality documentation, trade secrets, and development strategy.

A cell therapy partnership should clearly separate:

• Background IP
• Project IP
• Improvements
• manufacturing know-how
• regulatory data
• clinical data
• health-economic data
• commercialization rights
• publication rights
• sublicensing rights

Funding alone should not automatically transfer ownership of platform technology. Collaboration alone should not create an implied license. Technology transfer should be limited, phase-gated, field-limited, territory-limited, and tied to compliance, confidentiality, payment, and quality obligations.

For BioNK, this principle is central: partnership should accelerate development without diluting platform value.

Technology transfer is a controlled process, not a document dump

Technology transfer in cell therapy is high risk if not controlled.

A responsible technology transfer plan should define:

• what is transferred
• when it is transferred
• who receives it
• what it may be used for
• what may not be used
• what remains confidential
• what cannot be sublicensed
• what happens after termination
• what quality agreements are required
• what training is needed
• what audit rights apply
• what happens if funding or compliance fails

Technology transfer should not mean unrestricted platform access. It should mean controlled transfer of the minimum necessary information to perform approved development activities.

CMC and quality should be included in the business deal

In cell therapy, CMC is not an operational afterthought. It is a commercial and strategic asset.

A business-development agreement that does not address CMC risks is incomplete. For advanced therapies, the agreement should address:

• GMP/BPF readiness
• quality agreement requirements
• release responsibility
• deviation and CAPA management
• supplier qualification
• analytical method transfer
• stability
• sterility assurance
• chain of identity
• chain of custody
• shipping validation
• inspection readiness
• batch record control
• change control
• comparability

Before any GMP/BPF activity begins, a quality agreement should define the responsibilities of sponsor, manufacturer, QC laboratory, storage provider, logistics provider, and release-responsible party. See our companion piece on manufacturing and CMC.

Commercial terms must reflect value creation

Biotech partnerships fail when economics are disconnected from value contribution.

A sustainable deal should recognize the value of:

• platform technology
• background IP
• product know-how
• manufacturing know-how
• clinical development support
• regulatory data rights
• technology transfer
• analytical methods
• market access work
• sublicensing potential
• public-sector and private-sector channels

Possible economic structures may include:

• upfront payments
• technology access fees
• milestone payments
• royalties
• tiered royalties
• public-sector supply compensation
• private-market royalties
• sublicensing revenue share
• minimum annual royalties
• service fees
• cost-sharing
• equity or project-entity participation, where appropriate

The specific numbers depend on the transaction, risk, territory, field, development stage, funding level, partner contribution, and commercialization model. The principle is clear: BioNK’s contribution must remain economically protected.

Public-health access requires safeguards

Public-health access can be a legitimate strategic objective. It can also create financial and IP risk if poorly structured.

For Brazil and LATAM, advanced therapy access may involve public-sector stakeholders, public laboratories, reimbursement agencies, hospital networks, PDP/PDIL-type structures, or other policy instruments. These pathways require careful governance. See our perspective on Brazil and LATAM.

A responsible public-health access strategy should avoid:

• automatic public-sector exclusivity
• premature price commitments
• broad platform exclusivity
• unrestricted technology transfer
• supply commitments before COGS validation
• obligation to supply at a loss
• public procurement assumptions before legal validation
• waiver of BioNK compensation without board approval
• use of confidential know-how without defined rights

Access strategy and commercial sustainability should be designed together.

Partnership architecture in cell therapy